Welcome to our dedicated page for Cingulate SEC filings (Ticker: CINGW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cingulate's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cingulate's regulatory disclosures and financial reporting.
Director John A. Roberts of Cingulate was granted 15,000 stock options on June 20, 2025. The stock options have the following key terms:
- Exercise price set at $4.14 per share
- Expiration date of June 20, 2035 (10-year term)
- Vesting occurs at earlier of: - One-year anniversary of grant date - Date of Cingulate's 2026 annual stockholder meeting
This Form 4 filing, signed by Attorney-in-Fact Shane J. Schaffer on June 23, 2025, represents standard non-employee director equity compensation. The options provide Roberts with the right to purchase up to 15,000 shares of Cingulate common stock once vested. This grant aligns the director's interests with those of shareholders through long-term equity ownership potential.
Director Peter J. Werth of Cingulate received a stock option grant for 15,000 shares of common stock on June 20, 2025. The options were granted with an exercise price of $4.14 per share and will expire on June 20, 2035.
Key terms of the option grant:
- Vesting occurs at the earlier of: one-year anniversary of grant date or the 2026 annual stockholder meeting
- Transaction reported as a Form 4 filing indicating changes in beneficial ownership
- Options were acquired at no cost ($0) as part of director compensation
The filing was signed by Shane J. Schaffer as attorney-in-fact on June 23, 2025. This equity grant appears to be part of standard director compensation arrangements and represents a new beneficial ownership position for the reporting person.